SYSTEMIC ABSORPTION OF TOPICALLY APPLIED OCULAR DRUGS IN HUMANS

被引:84
作者
SALMINEN, L
机构
[1] Department of Ophthalmology, Tampere University Central Hospital, Tampere
来源
JOURNAL OF OCULAR PHARMACOLOGY | 1990年 / 6卷 / 03期
关键词
D O I
10.1089/jop.1990.6.243
中图分类号
R77 [眼科学];
学科分类号
100212 [眼科学];
摘要
Literature on human plasma concentrations after instillation of ocular timolol, levobunolol, atropine, cyclopentolate, scopolamine, phenylephrine, betamethasone and technetium Tc 99m and theories of lacrimal drainge were reviewed. In all studies the eyedrops absorbed rapidly into the systemic circulation. Like the kinetics of the tracer substances in lacrimal scintigraphy, the plasma drug levels showed interindividual variations. Plasma levels of ocular drugs were lower when punctal occlusion was applied, the mechamism, however, could not be explained. Since an early and a late plasma peak was occasionaly registered in some subjects in timolol and cyclopentolate studies, it is suggested that systemic absorption of ocular drugs is low during the nasolacrimal passage but occurs during conjunctival and nasal contact. © 1990, Mary Ann Liebert, Inc. All rights reserved.
引用
收藏
页码:243 / 249
页数:7
相关论文
共 28 条
[1]
Selvin B.L., Systemic effects of topical ophthalmic medication, In Clinical ophthalmic pharmacology, pp. 463-482, (1987)
[2]
Salminen L., Huupponen R., Systemic effects of ocular drugs.Adverse Drug React, Acute Poisoning Rev, 8, (1989)
[3]
Urtti A., Salminen L., Miinalainen O., Systemic absorption of ocular pilocarpine is modified by polymer matrices, Int. J. Pharm, 23, (1985)
[4]
Lee V.H.L., Robinson J.R., Review: Topical ocular drug delivery: Recent developments and future challenges, J. Ocul. Pharm, 2, (1986)
[5]
Duke-Elder S., System of ophthalmology, The foundations of ophthalmology: Heredity,pathology,diagnosis and therapeutics, VII, (1962)
[6]
Salminen L., Pakarinen P., Is the drop size of ophthalmic preparations equal and ideal, Fifth International Congress of Eye Research, (1982)
[7]
Lederer C.M., Harold R.E., Drop size of commercial glaucoma medication, Amer. J.Qphthalmol, 101, (1986)
[8]
Kass M.A., Hodapp E., Gordon M., Kolker A.E., Goldberg I., Part I. Patient administration of eyedrops: Interview, Ann. Ophthalmol, 14, (1982)
[9]
Kass M.A., Hodapp E., Gordon M., Kolker A.E., Goldberg I., Patient administration of eyedrops: Observation, Ann. Ophthalmol, 14, (1982)
[10]
Trueblood J.H., Rossomondo R.M., Carlton W.H., Wilson L.A., Corneal contact times of ophthalmic vehicles, Arch. Ophthalmol, 93, (1975)